Karyopharm Therapeutics Inc (KPTI) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Karyopharm Therapeutics Inc

NASDAQ | KPTI

3.86

USD

-0.2 (-4.93%)

AT CLOSE (AS OF Apr 3, 2025)

$34M

MARKET CAP

P/E Ratio

-13.95

EPS

$21

52 Week High

$3.5

52 Week Low

LIFE SCIENCES

Sector

KPTI Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

KPTI Technicals

Tags:

KPTI Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$74M
Total Revenue	$190M
Cost Of Revenue	$115M
Costof Goods And Services Sold	$6M
Operating Income	-$119M
Selling General And Administrative	$115M
Research And Development	$143M
Operating Expenses	$265M
Investment Income Net	$7.4M
Net Interest Income	-$30M
Interest Income	$7.4M
Interest Expense	$37M
Non Interest Income	$190M
Other Non Operating Income	$28M
Depreciation	$340K
Depreciation And Amortization	$340K
Income Before Tax	-$76M
Income Tax Expense	$57K
Interest And Debt Expense	-$7.3M
Net Income From Continuing Operations	-$76M
Comprehensive Income Net Of Tax	-$77M
Ebit	-$119M
Ebitda	-$39M
Net Income	-$76M

Revenue & Profitability

Earnings Performance

KPTI Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$164M
Total Current Assets	$156M
Cash And Cash Equivalents At Carrying Value	$62M
Cash And Short Term Investments	$109M
Inventory	$4.7M
Current Net Receivables	$31M
Total Non Current Assets	$6.6M
Property Plant Equipment	$400K
Accumulated Depreciation Amortization Ppe	$6.7M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$46M
Long Term Investments	-
Short Term Investments	$46M
Other Current Assets	-
Other Non Current Assets	-
Total Liabilities	$350M
Total Current Liabilities	$92M
Current Accounts Payable	$5.1M
Deferred Revenue	-
Current Debt	-
Short Term Debt	-
Total Non Current Liabilities	$104M
Capital Lease Obligations	-
Long Term Debt	$95M
Current Long Term Debt	-
Long Term Debt Noncurrent	$95M
Short Long Term Debt Total	$95M
Other Current Liabilities	$1.6M
Other Non Current Liabilities	$2.4M
Total Shareholder Equity	-$186M
Treasury Stock	-
Retained Earnings	-
Common Stock	$13K
Common Stock Shares Outstanding	$126M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	-$127M
Payments For Operating Activities	$39M
Proceeds From Operating Activities	-
Change In Operating Liabilities	$2M
Change In Operating Assets	$5.9M
Depreciation Depletion And Amortization	$4.2M
Capital Expenditures	$142K
Change In Receivables	$3.8M
Change In Inventory	$1.7M
Profit Loss	-$76M
Cashflow From Investment	$95M
Cashflow From Financing	$42M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	-
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	$83M
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$1.5M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$76M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$74M
Total Revenue	$190M
Cost Of Revenue	$115M
Costof Goods And Services Sold	$6M
Operating Income	-$119M
Selling General And Administrative	$115M
Research And Development	$143M
Operating Expenses	$265M
Investment Income Net	$7.4M
Net Interest Income	-$30M
Interest Income	$7.4M
Interest Expense	$37M
Non Interest Income	$190M
Other Non Operating Income	$28M
Depreciation	$340K
Depreciation And Amortization	$340K
Income Before Tax	-$76M
Income Tax Expense	$57K
Interest And Debt Expense	-$7.3M
Net Income From Continuing Operations	-$76M
Comprehensive Income Net Of Tax	-$77M
Ebit	-$119M
Ebitda	-$39M
Net Income	-$76M

KPTI Profile

Karyopharm Therapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217
PTIX	$0.43	91.50%	$4.04M	173,208,693

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

KPTI $3.86 (-4.93%) Quote details